The AMIGO2 (Adhesion Molecule with IgG-like domain 2) antibody is a tool used to study the AMIGO2 protein, a member of the AMIGO family of transmembrane proteins involved in cell adhesion and neurite outgrowth. AMIGO2. encoded by the *AMIGO2* gene, contains leucine-rich repeats and immunoglobulin-like domains, enabling interactions with extracellular components and signaling pathways. It is expressed in various tissues, including the nervous system, and plays roles in neuronal development, synapse formation, and cell survival.
Research has linked AMIGO2 to cancer progression, particularly in glioblastoma, hepatocellular carcinoma, and colorectal cancer, where its overexpression correlates with tumor invasion, metastasis, and poor prognosis. It is thought to modulate integrin signaling and extracellular matrix remodeling, promoting cancer cell migration.
Antibodies targeting AMIGO2 are utilized in techniques like Western blot, immunohistochemistry, and flow cytometry to detect protein expression and localization. These tools aid in elucidating AMIGO2’s biological functions and its potential as a therapeutic or diagnostic target. Both monoclonal and polyclonal AMIGO2 antibodies are available, with validation often performed in knockout models to ensure specificity. Ongoing studies focus on its mechanistic roles in disease and its utility in translational research.